Immuno-oncology Drugs Market

Immunotherapy is treatment that uses a certain part of a person?s immune system to fight diseases which is done by stimulating one?s own immune system to work harder to attack cancer cells or by giving immune system components, such as man-made immune system proteins. Immunotherapy includes treatments that work in different ways. Some boost the body?s immune system in a very general way and others help train the immune system to attack cancer cells specifically.

Immuno-oncology Drugs Market contains market size and forecasts of Immuno-oncology Drugs in global, including the following market information:

Global Immuno-oncology Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Immuno-oncology Drugs Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Immuno-oncology Drugs companies in 2021 (%)

The global Immuno-oncology Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Immune Checkpoint Inhibitors Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Immuno-oncology Drugs include Amgen, Inc, AstraZeneca, Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., Hoffmann-La Roche AG, Johnson & Johnson and Novartis International AG, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Immuno-oncology Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Immuno-oncology Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Immuno-oncology Drugs Market Segment Percentages, by Type, 2021 (%)

Immune Checkpoint Inhibitors

Immune System Modulators

Cancer Vaccines

Oncolytic Virus

Others

Global Immuno-oncology Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Immuno-oncology Drugs Market Segment Percentages, by Application, 2021 (%)

Hospitals

Clinics

Ambulatory Surgical Centers

Global Immuno-oncology Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Immuno-oncology Drugs Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Immuno-oncology Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Immuno-oncology Drugs revenues share in global market, 2021 (%)

Key companies Immuno-oncology Drugs sales in global market, 2017-2022 (Estimated), (K Units)

Key companies Immuno-oncology Drugs sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Amgen, Inc

AstraZeneca, Plc

Bristol-Myers Squibb

Celgene Corporation

Eli Lilly and Company

Merck & Co.

Hoffmann-La Roche AG

Johnson & Johnson

Novartis International AG

AbbVie, Inc.

Pfizer Inc.

Sanofi S.A.

EMD Serono, Inc.

Gilead Sciences Inc.

Prometheus Therapeutics & Diagnostics

Aduro BioTech

Galena Biopharma

Bavarian Nordic

Celldex Therapeutics

ImmunoCellular Therapeutics

Incyte

Dendreon Corporation

Agilent Technologies Inc.

Agenus Inc.

Enzo Biochem, Inc.

Lonza Group

Bio-Rad Laboratories, Inc.

Avantor, Inc.

Spring Bank Pharmaceuticals, Inc.

Ferring Pharmaceuticals